Chronic rhinosinusitis (CRS) is a persistent inflammatory condition of the nasal passages and paranasal sinuses lasting more than 12 weeks despite medical treatment, affecting an estimated 12% of the US adult population and representing one of the most prevalent chronic diseases globally. CRS encompasses two major phenotypes — chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP) — with distinct immunological drivers, treatment responses, and comorbidity profiles. Nasal polyps are benign, grape-like inflammatory outgrowths from the sinus mucosa occurring in 20–33% of CRS patients, strongly associated with type 2 (eosinophilic) inflammation, asthma, aspirin-exacerbated respiratory disease (AERD), and the emerging epidemic of mast cell activation. Despite widespread antibiotic use, CRS is fundamentally not an infectious disease — it is a chronic inflammatory disorder of the sinonasal immune barrier in which microbial dysbiosis, fungal colonization, biofilm formation, and immune dysregulation are the primary drivers.
Pathophysiology: The Inflamed Sinus
The sinonasal epithelium is a critical immune interface — ciliated pseudostratified epithelial cells, goblet cells, submucosal glands, and resident immune cells form a coordinated barrier that normally clears inhaled pathogens and particulates via mucociliary transport. CRS represents a failure of this barrier through multiple convergent mechanisms:
- Epithelial barrier dysfunction: Reduced expression of tight junction proteins (occludin, claudin-1, ZO-1) and epithelial-derived antimicrobial peptides (defensins, lactoferrin, lysozyme) impairs barrier integrity and innate immune defense. Environmental pollutants, cigarette smoke, and prior viral infections (especially rhinovirus) initiate barrier breakdown that perpetuates through chronic inflammation
- Type 2 eosinophilic inflammation (CRSwNP): Epithelial-derived alarmins — IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) — activate innate lymphoid cells type 2 (ILC2s) and Th2 lymphocytes, driving IL-4, IL-5, and IL-13 production. IL-5 recruits and prolongs eosinophil survival; IL-13 induces goblet cell hyperplasia and mucus hypersecretion; IL-4 promotes IgE class switching and mast cell sensitization. The resulting eosinophil-rich, IgE-high, edematous tissue forms the characteristic nasal polyp
- Type 1/neutrophilic inflammation (CRSsNP): Driven by Th1/Th17 cytokines (IFN-γ, IL-17, TNF-α), bacterial biofilms, and innate immune activation — producing neutrophil-dominated, fibrotic, less edematous mucosal thickening. More common in Asian populations; associated with staphylococcal biofilms
- Biofilm formation: Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenzae, and Streptococcus pneumoniae form polymicrobial biofilms on sinonasal mucosa — sessile bacterial communities encased in extracellular polymeric substance (EPS) matrices that are 100–1,000× more resistant to antibiotics and host immunity than planktonic bacteria. Staphylococcal biofilms additionally secrete superantigens (staphylococcal enterotoxin B/A) that non-specifically activate T cells and drive polyclonal IgE production, amplifying the type 2 inflammatory response independent of allergen sensitization
- Fungal colonization (fungal-driven CRS): Alternaria, Aspergillus, Cladosporium, and Candida colonize the sinonasal mucosa in most CRS patients — not causing invasive infection but triggering aberrant eosinophilic and IgE-mediated immune responses to fungal antigens. Alternaria alternata is particularly potent — directly activating sinonasal epithelial cells to release IL-33 and TSLP (alarmins), bypassing adaptive immunity to drive type 2 inflammation
- Mucociliary dysfunction: Impaired ciliary beat frequency (from inflammation, pollution, viral injury) and viscous mucus (from goblet cell hyperplasia) prevents normal sinus drainage — creating stagnant mucus pools that foster microbial growth, biofilm formation, and sustained antigen exposure
Root Causes & Risk Factors
Sinonasal Microbiome Dysbiosis
Healthy sinuses are not sterile — a commensal microbiome dominated by Lactobacillus, Staphylococcus epidermidis, Corynebacterium, and Propionibacterium maintains homeostasis and competitively excludes pathogens. CRS patients demonstrate loss of microbiome diversity and depletion of Lactobacillus species — creating a permissive environment for S. aureus biofilm dominance. Repeated antibiotic courses further dysregulate this microbiome, creating a vicious cycle. Cross-reference: Leaky Gut & Microbiome Dysbiosis.
Fungal Sensitization & Colonization
The Mayo Clinic's landmark 1999 study identified fungal elements in 96% of CRS surgical specimens — recasting CRS as primarily a fungal-driven immune response rather than bacterial infection. Sensitization to fungal allergens (particularly Alternaria) is strongly associated with CRSwNP severity and treatment resistance. Environmental mold exposure (indoor mold, occupational) is a major modifiable trigger. Cross-reference: Mycotoxins, Mold & Hepatic Stress.
Allergic Rhinitis & Atopy
Allergic rhinitis (type 1 IgE-mediated hypersensitivity to aeroallergens) is present in 40–60% of CRS patients — allergen-driven Th2 inflammation and IgE-mediated mast cell activation amplify sinonasal eosinophilia and polyp formation. House dust mite, mold, pet dander, and pollen are primary triggers. Effective allergy management is prerequisite to CRS control in atopic patients.
Aspirin-Exacerbated Respiratory Disease (AERD / Samter's Triad)
AERD affects ~10% of CRSwNP patients — a distinct phenotype combining severe nasal polyps, asthma, and hypersensitivity to aspirin/NSAIDs (via COX-1 inhibition diverting arachidonic acid toward 5-LOX and excessive leukotriene C4/D4 production). Extraordinarily high mast cell burden, severe eosinophilia, and rapid polyp recurrence post-surgery characterize AERD. Aspirin desensitization (under physician supervision) is the most effective long-term intervention. Leukotriene-modifying agents (montelukast, zileuton) are standard adjuncts.
Mast Cell Activation
Mast cell activation syndrome (MCAS) significantly overlaps with CRSwNP — elevated prostaglandin D2, histamine, and tryptase drive nasal congestion, mucus hypersecretion, and polyp eosinophilia independent of IgE-mediated allergy. Salicylate sensitivity, multiple chemical sensitivities, and refractory CRS despite biologics should prompt MCAS evaluation. Cross-reference: Chronic Illness Hub.
Structural & Anatomical Factors
Deviated nasal septum, concha bullosa, paradoxically curved middle turbinate, and narrow osteomeatal complex (OMC) impair sinus drainage and ventilation — creating hypoxic, stagnant environments favorable to biofilm formation. CT sinus imaging characterizes anatomical obstruction guiding surgical planning.
Environmental & Occupational Exposures
Cigarette smoke (active and passive) — directly impairs mucociliary clearance, increases biofilm susceptibility, and drives neutrophilic airway inflammation. Occupational exposures: wood dust, flour, chemical fumes (hairdressers, painters, farmers) — associated with CRS and nasal polyp development. Indoor mold and poor indoor air quality — major modifiable contributors.
Nutritional Deficiencies
Vitamin D deficiency is strongly associated with CRS severity, polyp recurrence after surgery, and impaired sinonasal innate immunity (reduced antimicrobial peptide production). Zinc deficiency impairs ciliary function, epithelial barrier repair, and mucosal immune response. Omega-3 deficiency shifts eicosanoid balance toward pro-inflammatory leukotrienes — directly relevant to leukotriene-driven polyp pathology.
Diagnosis
CRS diagnosis requires: ≥2 cardinal symptoms (nasal obstruction/congestion, mucopurulent drainage, facial pain/pressure/fullness, reduced/absent smell) for >12 weeks PLUS objective evidence of sinonasal inflammation (endoscopic findings OR CT changes). Key investigations:
- Nasal endoscopy: Polyps, mucopurulent discharge, mucosal edema — graded by Lund-Kennedy score; essential for diagnosis and treatment monitoring
- CT sinus (without contrast): Lund-Mackay score quantifies mucosal thickening across sinus groups; identifies anatomical variants and complications; guides surgical planning
- Allergy testing: Skin prick testing or specific IgE (ImmunoCAP) for aeroallergens; total IgE, blood eosinophil count, serum tryptase
- Tissue biomarkers: Polyp eosinophil count, tissue IgE, IL-5 — predict biological therapy response
- Aspirin challenge: For suspected AERD — performed under physician supervision; urinary LTE4 (markedly elevated in AERD)
- Fungal workup: Fungal culture of nasal mucus; Alternaria-specific IgE; total IgE
Conventional Treatment
Intranasal Corticosteroids (INCS)
First-line for all CRS phenotypes — fluticasone propionate, mometasone, budesonide, triamcinolone. Reduce mucosal eosinophilia, polyp size, and symptom burden. Delivery is critical — standard nasal sprays poorly reach posterior ethmoid and sphenoid sinuses. High-volume nasal irrigation with budesonide (0.5–1mg in 240ml saline) dramatically improves drug delivery to affected tissue. Exhalation delivery system (Xhance) delivers fluticasone under positive pressure to upper sinuses. Nasal steroid sprays reduce polyp size by 40–50% and delay time to surgery. Systemic side effects minimal with standard dosing.
Nasal Saline Irrigation
High-volume (240ml), isotonic or hypertonic saline irrigation (Neti pot, NeilMed squeeze bottle, or positive-pressure devices) — mechanically removes mucus, allergens, biofilm, and inflammatory mediators; restores mucociliary transport; reduces symptom scores comparably to INCS in mild CRS. Should be first-line in all CRS patients. Isotonic for maintenance; hypertonic (2–3% saline) for acute symptom control (superior mucolytic effect). Add xylitol or baby shampoo (0.05% dilution) to saline for biofilm disruption.
Oral/Systemic Corticosteroids
Short courses (prednisone 30–50mg/day for 5–14 days) for acute CRS exacerbations and pre-/post-operative polyp reduction. Highly effective short-term — reduce polyp size, restore smell, improve quality of life. Not appropriate for long-term maintenance due to systemic side effects (adrenal suppression, glucose intolerance, bone density loss, immune suppression).
Antibiotics
Appropriate for acute bacterial superinfection (purulent discharge, facial pain, fever) — amoxicillin-clavulanate first-line; doxycycline or respiratory fluoroquinolone for PCN allergy. Long-term low-dose macrolides (azithromycin 250mg 3×/week or roxithromycin) for CRSsNP with low IgE — anti-inflammatory macrolide effect (NF-κB suppression, biofilm disruption, mucokinesis) independent of antibiotic effect. Macrolide therapy is NOT appropriate for type 2/eosinophilic CRS (may worsen by reducing competing bacterial signals).
Leukotriene-Modifying Agents
Montelukast (Singulair, 10mg/day) and zileuton (Zyflo) block leukotriene signaling — directly relevant to AERD, aspirin-sensitive polyps, and asthma comorbidity. Zileuton (5-LOX inhibitor) reduces urinary LTE4 by 60–70% in AERD — more potent than montelukast (CysLT1 receptor antagonist) but requires liver function monitoring.
Biological Therapies (Severe CRSwNP)
- Dupilumab (Dupixent): Anti-IL-4Rα (blocks both IL-4 and IL-13 signaling) — FDA-approved for CRSwNP; reduces polyp size by 50–60%, restores smell in 65%, reduces need for systemic steroids and revision surgery. Monthly or biweekly SC injection. Most robust efficacy data of available biologics
- Mepolizumab (Nucala): Anti-IL-5 — reduces eosinophil recruitment; FDA-approved for CRSwNP; monthly SC injection; particularly effective in high blood eosinophil/tissue eosinophil CRSwNP
- Omalizumab (Xolair): Anti-IgE — FDA-approved for CRSwNP; reduces mast cell sensitization and IgE-mediated eosinophil activation; monthly/biweekly SC; most effective in high total IgE, atopic CRSwNP
- Benralizumab (Fasenra): Anti-IL-5Rα (depletes eosinophils more completely than mepolizumab); approved for eosinophilic asthma; clinical trials positive for CRSwNP
Endoscopic Sinus Surgery (ESS)
Functional endoscopic sinus surgery (FESS) opens sinus ostia, removes polyps, and restores ventilation and drainage — creating an environment where topical medications can reach sinus mucosa. Not curative in type 2 CRS — polyps recur in 40–60% within 3–5 years without ongoing medical management. Surgery is most effective when combined with postoperative high-volume budesonide irrigation and, in severe disease, biological therapy. Balloon sinuplasty: office-based, catheter-based sinus dilation for CRSsNP without polyps — less tissue disruption, faster recovery.
Repurposed Drugs with CRS Evidence
Doxycycline
Beyond antibiotic effects, doxycycline has significant anti-inflammatory properties — inhibiting matrix metalloproteinase (MMP)-9, reducing neutrophil degranulation, and suppressing NF-κB. A landmark RCT demonstrated doxycycline 200mg loading then 100mg/day for 20 days reduced nasal polyp size significantly vs. placebo — independent of antimicrobial effect, likely through MMP inhibition and type 2 inflammation dampening. Represents a low-cost, accessible option for CRSwNP. Reference: Van Zele T et al., J Allergy Clin Immunol, 2010.
Aspirin Desensitization (AERD)
For confirmed AERD — supervised aspirin desensitization (starting at 20–40mg and incrementally increasing to 650mg twice daily over 3 days under monitoring) induces tolerance and reduces leukotriene overproduction long-term. Post-desensitization aspirin 650mg twice daily maintenance reduces polyp recurrence, improves asthma control, and reduces revision surgery rates in AERD — the most disease-modifying intervention available for this phenotype. Performed at specialized centers.
Itraconazole (Antifungal)
For fungal-driven CRS — oral itraconazole (200mg twice daily) or voriconazole reduces fungal burden and may reduce eosinophilic inflammation driven by fungal antigens. RCTs show modest benefit in a subset of CRS patients, particularly those with demonstrable fungal sensitization (elevated Alternaria IgE). Liver function monitoring required. Topical antifungal irrigation (itraconazole 100mg/100ml saline, or amphotericin B 100mcg/ml) avoids systemic side effects — evidence base limited but used clinically.
Low-Dose Naltrexone (LDN)
Emerging use in mast cell activation-driven CRS and MCAS-associated nasal polyps — TLR4 modulation reduces mast cell degranulation, prostaglandin D2 release, and neurogenic inflammation contributing to nasal congestion and polyp formation. Particularly relevant in AERD and salicylate-sensitive CRS. Dose: 1.5–4.5mg nightly. Cross-reference: Low-Dose Naltrexone: Complete Guide.
Metformin
AMPK activation reduces mTOR-driven eosinophil survival and type 2 cytokine production — mechanistically relevant to eosinophilic CRSwNP. Animal models show metformin reduces nasal polyp formation via mTOR inhibition and PI3K/Akt suppression. Also reduces the metabolic comorbidities (obesity, insulin resistance) that worsen eosinophilic airway disease severity.
Vitamins, Supplements & Compounds
Vitamin D3 + K2
Vitamin D deficiency correlates directly with CRS severity scores and polyp recurrence rate. Vitamin D3 at adequate levels: stimulates sinonasal epithelial production of cathelicidin (LL-37) and defensins (innate antimicrobial peptides essential for sinonasal defense), reduces TSLP and IL-33 alarmin release from epithelial cells, and promotes regulatory immune responses dampening type 2 inflammation. Multiple studies confirm lower 25(OH)D in CRS patients vs. controls, with severity inversely proportional to vitamin D level. Target 25(OH)D: 60–80 ng/mL. Dose: 5,000–8,000 IU/day D3 + K2 MK-7 100mcg. Reference: Mulligan JK et al., Am J Rhinol Allergy, 2011.
Omega-3 Fatty Acids (EPA/DHA)
Arachidonic acid-derived prostaglandins and leukotrienes drive polyp eosinophilia and mast cell activation — omega-3s competitively reduce arachidonic acid availability and generate specialized pro-resolving mediators (resolvins, protectins) that actively resolve eosinophilic inflammation. Particularly relevant for AERD — reducing leukotriene burden and mast cell reactivity. Also improve mucosal barrier function and reduce systemic atopic inflammation. Dose: 3–4g EPA+DHA daily. Avoid fish oil in true aspirin/NSAID sensitivity until tolerance confirmed. Reference: Mickleborough TD, Chest, 2005.
Quercetin
A natural mast cell stabilizer and 5-LOX/COX inhibitor — quercetin inhibits histamine release, prostaglandin D2, and leukotriene C4 from mast cells and basophils (mechanistically similar to cromolyn sodium). Reduces eosinophil chemotaxis and IgE-mediated sensitization. Particularly relevant for AERD, MCAS-driven CRS, and allergic CRS. Dose: 500–1,000mg quercetin phytosome (high-bioavailability form) twice daily. Cross-reference: Quercetin: The Master Flavonoid. Reference: Shaik YB et al., Eur J Pharmacol, 2006.
N-Acetylcysteine (NAC)
A mucolytic (breaks disulfide bonds in mucus glycoproteins, reducing viscosity) and antioxidant — NAC improves mucociliary clearance, reduces biofilm formation (disrupts EPS matrix of bacterial biofilms), and replenishes sinonasal glutathione. Oral NAC 600mg twice daily reduces mucus viscosity and improves sinus drainage. Also available as nasal irrigation additive (600mg/100ml saline) for direct biofilm disruption — used in clinical sinus centers. Reference: Benninger MS et al., Otolaryngol Head Neck Surg, 1997.
Bromelain
A pineapple-derived protease enzyme with mucolytic, anti-inflammatory, and sinus drainage-promoting properties. Bromelain reduces nasal mucosal edema by degrading bradykinin and fibrin; inhibits prostaglandin and leukotriene synthesis; and improves nasal airflow. A German RCT demonstrated bromelain (Sinupret combination) significantly reduced CRS symptom duration vs. standard therapy alone. Take on empty stomach for systemic anti-inflammatory effect; with food for GI mucolytic effect. Dose: 500–1,000mg (2,400 GDU/g standardized) 2–3× daily between meals. Reference: Guo R et al., QJM, 2006.
Zinc (Intranasal + Oral)
Zinc deficiency impairs mucociliary beat frequency, sinonasal epithelial repair, and innate immune antimicrobial peptide production. Zinc gluconate intranasal formulations (Cold-Eeze) reduce viral rhinitis — highly relevant given viral triggers of CRS exacerbations. Oral zinc glycinate 15–25mg daily supports barrier integrity and immune function. Note: intranasal zinc sulfate (Zicam original formulation) caused anosmia — only gluconate/acetate forms are safe intranasally.
Probiotics (Gut & Nasal)
Gut microbiome restoration reduces systemic type 2 inflammation and atopic sensitization — butyrate-producing gut bacteria downregulate TSLP and IL-33 alarmin production at mucosal surfaces. Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12 have specific evidence for reducing allergic rhinitis symptom scores and eosinophilic airway inflammation. Nasal probiotics — Lactobacillus sakei (a dominant nasal commensal depleted in CRS) — are being studied to restore sinonasal microbiome homeostasis. Dose: 50+ billion CFU multi-strain gut probiotic daily. Reference: Ouwehand AC et al., Allergy, 2009.
Butterbur (Petasites hybridus — Petasin)
Petasin and isopetasin are potent 5-LOX and COX inhibitors — comparable to cetirizine for allergic rhinitis in head-to-head RCTs, without antihistamine sedation or mucosal drying. Directly reduces leukotriene synthesis relevant to AERD and polyp formation. Only use PA-free (pyrrolizidine alkaloid-free) standardized extracts — raw plant contains hepatotoxic PAs. Dose: 50–75mg standardized extract (7.5mg petasin) twice daily. Reference: Schapowal A, BMJ, 2002.
Vitamin C (Liposomal)
Antihistamine effect (vitamin C degrades histamine enzymatically via diamine oxidase), antioxidant protection for sinonasal mucosa, supports collagen synthesis for epithelial barrier repair, and reduces mast cell degranulation threshold. Dose: 1,000–2,000mg liposomal vitamin C daily; increase to 3–4g during exacerbations. Also supports immune response to viral triggers of CRS exacerbations.
Botanical Treatments
Sinupret (European Botanical Combination)
The most clinically studied CRS botanical — a proprietary combination of elderflower, sorrel, cowslip, verbena, and gentian root with combined secretolytic, mucokinetic, and mild antiviral properties. Multiple RCTs and a systematic meta-analysis confirm Sinupret reduces sinusitis symptom duration, antibiotic requirement, and radiological evidence of sinusitis vs. placebo. Licensed as a pharmaceutical sinusitis treatment in Germany. Adult dose: Sinupret Extract 160mg 3× daily. Reference: Bachert C et al., HNO, 2009.
Eucalyptus Oil (1,8-Cineole / Eucalyptol)
1,8-Cineole is a potent mucolytic, secretomotor, and anti-inflammatory monoterpene — reduces mucus viscosity, stimulates mucociliary beat frequency, inhibits NF-κB, and suppresses leukotriene and prostaglandin synthesis. A RCT in acute rhinosinusitis demonstrated 200mg 1,8-cineole 3× daily for 7 days was non-inferior to standard treatment. For CRS, particularly effective for reducing thick, viscous mucus and improving sinus drainage. Also available as eucalyptus steam inhalation — add 5–10 drops to hot water and inhale steam for 10 minutes. Oral: 200mg standardized eucalyptol capsules 3× daily. Reference: Kehrl W et al., Laryngoscope, 2004.
Horseradish & Wasabi (Armoracia rusticana)
Allyl isothiocyanate (AITC) from horseradish and wasabi activates TRPA1 channels in sinonasal mucosa — triggering immediate mucus thinning, sinus drainage, and reflexive nasal secretion (the familiar tear-inducing effect of wasabi). Pharmaceutically formulated as Sinol-M nasal spray (horseradish extract nasal spray) studied in CRS. Also consumed as fresh grated horseradish or capsule form — traditional sinus remedy with pharmacological basis. Dose: fresh horseradish 1–2 tsp daily with food; or standardized capsule 300–500mg.
Stinging Nettle (Urtica dioica — Leaf Extract)
A natural antihistamine and 5-LOX inhibitor — nettle leaf extract inhibits NF-κB, reduces TNF-α and IL-1β, and blocks prostaglandin formation comparable to some NSAIDs. A placebo-controlled trial demonstrated freeze-dried nettle leaf (300mg twice daily) was rated moderately to highly effective for allergic rhinitis by 58% of participants. Particularly useful for the allergic component of CRS. Dose: 300–600mg freeze-dried leaf extract twice daily. Reference: Mittman P, Planta Med, 1990.
Andrographis (Andrographis paniculata)
Andrographolide — potent NF-κB inhibitor and interferon inducer — reduces viral rhinitis severity and duration (directly relevant to viral-triggered CRS exacerbations), inhibits neutrophilic airway inflammation, and reduces bacterial adhesion to respiratory epithelium. Combine with echinacea during viral exacerbations for synergistic antiviral and anti-inflammatory effect. Dose: 200–400mg andrographolide standardized extract at infection onset; 100–200mg daily for maintenance in frequent exacerbators.
Goldenseal (Hydrastis canadensis — Berberine/Hydrastine)
Berberine is a potent antimicrobial against S. aureus biofilms — reducing biofilm formation, disrupting mature biofilms, and restoring antibiotic sensitivity to resistant organisms. Hydrastine reduces mucosal edema and acts as a mild nasal decongestant. Goldenseal was the pre-antibiotic era standard of care for sinusitis. Also anti-Candidal — relevant for fungal sinonasal colonization. Dose: 500mg standardized goldenseal root extract (10% alkaloids) 3× daily for acute infection; berberine 500mg 2–3× daily for ongoing biofilm management. Cross-reference: Berberine: The Natural Metformin.
Thyme (Thymus vulgaris) & Ivy Leaf (Hedera helix)
Thymol and carvacrol stimulate mucociliary clearance, disrupt S. aureus and P. aeruginosa biofilms, and exert direct antimicrobial activity. Ivy leaf saponins (alpha-hederin) increase beta-2 receptor density on airway smooth muscle and stimulate surfactant production, thinning mucus. Bronchipret (thyme+ivy combination) — a registered German phytomedicine — reduces CRS and bronchitis symptom duration in multiple RCTs. Dose: thyme fluid extract 2ml 3× daily; or Bronchipret formulation as directed.
Curcumin (Curcuma longa)
NF-κB suppression, eosinophil chemotaxis inhibition, leukotriene reduction, and Th2-to-Th1 immune rebalancing — curcumin addresses multiple CRS pathways. Reduces TSLP and IL-33 alarmin release from epithelial cells in vitro. Use bioavailable formulation. Dose: 500–1,000mg BCM-95 or phytosome curcumin daily. Cross-reference: Curcumin: The Gold Standard Anti-Inflammatory Botanical.
Environmental & Lifestyle Interventions
- Indoor air quality: HEPA air purifiers in bedroom and living areas; address indoor mold (professional remediation if necessary — not just surface cleaning); avoid synthetic fragrances, cleaning chemicals, and VOCs that trigger mast cell activation and mucosal irritation
- Diet: Anti-inflammatory diet reducing arachidonic acid (red meat, vegetable oils) and increasing omega-3s; low-histamine diet for mast cell-driven CRS; eliminate salicylates in AERD until desensitized; dairy elimination trial (mucus-thickening effect is debated but clinically relevant in some patients)
- Nasal hygiene: Daily high-volume saline irrigation (240ml) — the single most impactful self-management intervention; humidification in dry environments; avoid nose blowing forcefully (increases intrasinus pressure, driving infected mucus into middle ear)
- Smoking cessation: The most impactful modifiable behavioral factor — smoking directly impairs mucociliary clearance and is incompatible with CRS management
- Allergy immunotherapy (AIT): Subcutaneous or sublingual immunotherapy for aeroallergen-sensitized CRS patients — reduces atopic burden and leukotriene-driven polyp inflammation over 3–5 year course; the only disease-modifying intervention for allergic rhinitis
Integrated Protocol by Phenotype
CRSsNP (Neutrophilic / Non-Eosinophilic)
- High-volume saline irrigation daily (240ml, hypertonic or isotonic)
- Intranasal corticosteroid spray (fluticasone or mometasone)
- NAC 600mg twice daily (mucolytic + biofilm disruption)
- Vitamin D3: 5,000–8,000 IU/day
- Eucalyptol 200mg 3× daily
- Goldenseal/berberine 500mg 2–3× daily (S. aureus biofilm)
- Sinupret Extract 160mg 3× daily
- Discuss long-term macrolide (azithromycin 3×/week) with ENT for recalcitrant cases
CRSwNP (Eosinophilic / Type 2)
- High-volume budesonide-saline irrigation (0.5mg budesonide in 240ml saline daily)
- Intranasal corticosteroid (Xhance delivery system preferred)
- Quercetin phytosome 500–1,000mg twice daily
- Omega-3 EPA/DHA 3–4g daily
- Vitamin D3: 5,000–8,000 IU/day
- Curcumin BCM-95 500mg daily
- Bromelain 500mg 3× daily between meals
- For biologics-eligible patients: discuss dupilumab with ENT/allergist
AERD (Aspirin-Exacerbated)
- Strict aspirin/NSAID avoidance until desensitized; discuss formal desensitization with allergist
- Zileuton (Rx) or montelukast for leukotriene suppression
- Quercetin (mast cell stabilization)
- Omega-3 3–4g (arachidonic acid competition)
- Butterbur 50–75mg PA-free twice daily (5-LOX inhibition)
- LDN 4.5mg nightly (mast cell/neurogenic inflammation)
- Low-salicylate diet during active flares
Fungal-Driven CRS
- Address indoor mold exposure (air quality testing, remediation)
- Antifungal nasal irrigation (compounded amphotericin B 100mcg/ml or itraconazole solution)
- Discuss oral itraconazole with ENT for sensitized patients
- Quercetin + curcumin (eosinophilic inflammation from fungal antigens)
- Saccharomyces boulardii + gut probiotics (gut-lung-sinus axis)
- Berberine 500mg 2–3× daily (antifungal + antibiofilm)
Key Citations
- Fokkens WJ et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (EPOS2020). Rhinology. 2020;58(Suppl S29):1-464.
- Van Zele T et al. Oral steroids and doxycycline: two different approaches to treat nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069-1076.
- Mulligan JK et al. Vitamin D3 deficiency increases severity of chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2011;25(6):e197-200.
- Bachert C et al. Sinupret for Treatment of Acute and Chronic Sinusitis. HNO. 2009.
- Kehrl W et al. Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial. Laryngoscope. 2004;114(4):738-742.
- Schapowal A. Randomised controlled trial of butterbur and cetirizine for treating seasonal allergic rhinitis. BMJ. 2002;324(7330):144-146.
- Shaik YB et al. Role of quercetin in allergy and mast cell stabilization. Eur J Pharmacol. 2006.
- Mickleborough TD et al. Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes. Chest. 2006;129(1):39-49.
0 comments